로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Angiopoietin-like 3

Angiopoietin-like 3

요약

Name:Angiopoietin like 3
Target Synonym:Angiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

제품 리스트 구매

일부의 생물활성 데이터

AN3-H52H3-ELISA
 Angiopoietin-like 3 ELISA

Immobilized Human Angiopoietin-like 3, His Tag (Cat. No. AN3-H52H3) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ANGPTL3 Antibody, Human IgG1 with a linear range of 0.5-2 ng/mL (QC tested).

AN3-H5253-ELISA
 Angiopoietin-like 3 ELISA

Immobilized Human Angiopoietin-like 3 Protein, Fc Tag (Cat. No. AN3-H5253) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ANGPTL3 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

Synonym Name

ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2

Background

Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Evinacumab REGN-1500 Approved Evkeeza United States Hypercholesterolemia; Homozygous familial hypercholesterolemia Regeneron Pharmaceuticals Inc 2021-02-11 Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Hypercholesterolemia; Metabolic Diseases Details
Evinacumab REGN-1500 Approved Evkeeza United States Hypercholesterolemia; Homozygous familial hypercholesterolemia Regeneron Pharmaceuticals Inc 2021-02-11 Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Hypercholesterolemia; Metabolic Diseases Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Plozasiran ARO-APOC3 Phase 3 Clinical Arrowhead Pharmaceuticals Inc Hypertriglyceridemia; Hyperlipoproteinemia Type I; Dyslipidemias Details
LNA-043 LNA-043 Phase 2 Clinical Novartis Pharma Ag Knee Injuries; Osteoarthritis, Knee; Osteoarthritis Details
Vupanorsen ISIS-703802; PF-07285557 Phase 2 Clinical Ionis Pharmaceuticals Inc Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hyperlipoproteinemia Type I; Hyperlipoproteinemias; Dyslipidemias; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II Details
SHR-1918 SHR-1918; SHR1918 Phase 2 Clinical Homozygous familial hypercholesterolemia; Hyperlipidemias Details
LY-3561774 LY-3561774; DCR-CM-1; DCR-CM1 Phase 2 Clinical Dicerna Pharmaceuticals Inc Metabolic Diseases; Dyslipidemias; Hyperlipoproteinemias; Cardiovascular Diseases; Lipid Metabolism Disorders Details
Zodasiran ARO-ANG3; VSA-003(Arrowhead Pharmaceuticals) Phase 2 Clinical Arrowhead Pharmaceuticals Inc Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Dyslipidemias; Hyperlipoproteinemia Type II Details
LY-3475766 LY-3475766 Phase 1 Clinical Eli Lilly And Company Dyslipidemias Details
JS-401 JS-401 Phase 1 Clinical Shanghai Junshi Biological Engineering Co Ltd Hyperlipidemias Details
AZD-1705 AZD1705; AZD-1705 Phase 1 Clinical Parexel, Astrazeneca Plc Cardiovascular Diseases Details
Plozasiran ARO-APOC3 Phase 3 Clinical Arrowhead Pharmaceuticals Inc Hypertriglyceridemia; Hyperlipoproteinemia Type I; Dyslipidemias Details
LNA-043 LNA-043 Phase 2 Clinical Novartis Pharma Ag Knee Injuries; Osteoarthritis, Knee; Osteoarthritis Details
Vupanorsen ISIS-703802; PF-07285557 Phase 2 Clinical Ionis Pharmaceuticals Inc Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hyperlipoproteinemia Type I; Hyperlipoproteinemias; Dyslipidemias; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II Details
SHR-1918 SHR-1918; SHR1918 Phase 2 Clinical Homozygous familial hypercholesterolemia; Hyperlipidemias Details
LY-3561774 LY-3561774; DCR-CM-1; DCR-CM1 Phase 2 Clinical Dicerna Pharmaceuticals Inc Metabolic Diseases; Dyslipidemias; Hyperlipoproteinemias; Cardiovascular Diseases; Lipid Metabolism Disorders Details
Zodasiran ARO-ANG3; VSA-003(Arrowhead Pharmaceuticals) Phase 2 Clinical Arrowhead Pharmaceuticals Inc Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Dyslipidemias; Hyperlipoproteinemia Type II Details
LY-3475766 LY-3475766 Phase 1 Clinical Eli Lilly And Company Dyslipidemias Details
JS-401 JS-401 Phase 1 Clinical Shanghai Junshi Biological Engineering Co Ltd Hyperlipidemias Details
AZD-1705 AZD1705; AZD-1705 Phase 1 Clinical Parexel, Astrazeneca Plc Cardiovascular Diseases Details

This web search service is supported by Google Inc.

totop